Rosemary
*Rosmarinus officinalis*
Evidence Rating
D Fair
Confidence Level
Low
Commission E and EMA approved for traditional use, but clinical trial evidence is very limited. Most evidence derives from pharmacological studies and traditional documentation rather than RCTs.
Traditions
Western
Last Updated
2/12/2026
Summary
Rosemary is a traditional European medicinal herb approved by Commission E for dyspeptic complaints (internal use) and as supportive therapy for rheumatic diseases (external use). The EMA grants traditional use status for mild digestive disorders and mild muscle/joint pain. ESCOP has not published a monograph for rosemary. The leaf contains rosmarinic acid, carnosic acid, carnosol, and a complex essential oil rich in 1,8-cineole, camphor, and borneol. Clinical trial evidence is very limited -- the evidence base rests primarily on pharmacological plausibility, long traditional use, and the well-characterized antioxidant and spasmolytic properties of its constituents. Rosemary occupies a complementary role alongside peppermint and other carminatives in the European phytotherapy approach to functional dyspepsia.
Regulatory Status
| Regulatory Body | Status |
|---|---|
| Commission E (Germany) | ✓ Approved |
| ESCOP (European) | — |
| EMA/HMPC (EU) | ✓ Approved |
Metadata
| Field | Detail |
|---|---|
| Common Names (English) | Rosemary |
| Common Names (German) | Rosmarin |
| Botanical Name | Rosmarinus officinalis L. (syn. Salvia rosmarinus Spenn.) |
| Plant Family | Lamiaceae (Labiatae) |
| Part Used | Leaves and flowering tops (Rosmarini folium); also rosemary essential oil (Rosmarini aetheroleum) for external use |
| Key Constituents | Rosmarinic acid, carnosic acid, carnosol, 1,8-cineole (eucalyptol), camphor, alpha-pinene, borneol, ursolic acid |
| Major Standardized Extracts | No widely recognized standardized extract equivalent to products like EGb 761 or Remifemin; rosemary preparations are typically traditional herbal medicines |
| Evidence Quality Rating | Preliminary — Commission E approved, EMA traditional use; very limited clinical trial data |
Approved Indications
Commission E (Germany, 1990)
- Internal use: Dyspeptic complaints
- External use: Supportive therapy for rheumatic diseases and circulatory disorders (as bath additive or topical preparation)
ESCOP
- No ESCOP monograph has been published for rosemary leaf
EMA/HMPC (European Medicines Agency)
- Status: Traditional Use
- Indications (internal):
- Relief of mild spasmodic disorders of the gastrointestinal tract (flatulence, bloating)
- Symptomatic treatment of mild digestive disorders (dyspepsia)
- Indications (external/topical):
- Adjuvant treatment of minor muscular and articular pain
- Improvement of minor peripheral circulatory disorders (traditional)
- Monograph Reference: EMA/HMPC/13631/2009 (Rosmarinus officinalis L., folium and aetheroleum)
- Duration: If symptoms persist beyond 2 weeks of use, a physician should be consulted
Agreement/Disagreement Between Bodies
- Agreement: Commission E and EMA agree on dyspeptic complaints (internal) and supportive rheumatic/musculoskeletal use (external) as the core indications
- Notable: ESCOP has not published a rosemary monograph, which reflects the limited clinical trial evidence base
- Nuance: The EMA specifically mentions spasmodic GI disorders, while Commission E uses the broader term “dyspeptic complaints”
- External use: Both Commission E and EMA agree on topical application for rheumatic and circulatory complaints, primarily as bath additive or rubbing preparation
Conditions Treated
Primary (Strong Evidence)
- Functional dyspepsia: Bloating, flatulence, sensation of fullness — supported by Commission E approval and pharmacological plausibility (spasmolytic, choleretic)
- Minor muscle and joint pain (topical): Used as bath additive or rubefacient preparation for rheumatic complaints
Secondary (Moderate Evidence)
- Peripheral circulatory disorders (topical): Traditional use as stimulating bath additive to improve peripheral blood flow
- Appetite loss: Traditional bitter-aromatic digestive stimulant
Traditional/Historical (Limited Evidence)
- Headache and migraine (topical application of essential oil to temples)
- Mental fatigue and concentration difficulties (aromatherapy use)
- Hair loss and scalp conditions (topical rinse or oil application)
- Wound healing and skin care (topical)
- Hepatoprotection (preclinical data only)
Mechanism of Action
Primary Mechanisms
Spasmolytic/Carminative (GI tract):
- Rosemary essential oil components (1,8-cineole, borneol, camphor) exert direct smooth muscle relaxant effects on gastrointestinal smooth muscle
- Carnosic acid and rosmarinic acid contribute to choleretic activity, increasing bile flow and thereby improving fat digestion
- The bitter-aromatic profile stimulates gastric and salivary secretions via gustatory reflex pathways
Anti-inflammatory/Analgesic (topical use):
- Camphor and 1,8-cineole provide local rubefacient and mild analgesic effects when applied topically
- Rosmarinic acid inhibits complement activation and lipoxygenase/cyclooxygenase pathways
- Ursolic acid contributes additional anti-inflammatory activity
Secondary Mechanisms
| Compound | Activity |
|---|---|
| Rosmarinic acid | Antioxidant (potent radical scavenger), anti-inflammatory (COX-2 and 5-LOX inhibition), choleretic |
| Carnosic acid / Carnosol | Among the most potent natural antioxidants known; neuroprotective in preclinical models (Nrf2 pathway activation); antimicrobial |
| 1,8-Cineole (Eucalyptol) | Spasmolytic, mucolytic, anti-inflammatory |
| Camphor | Rubefacient, local analgesic, CNS stimulant at low doses |
| Borneol | Spasmolytic, enhances transdermal absorption of other compounds |
| Ursolic acid | Anti-inflammatory, hepatoprotective (preclinical) |
| Alpha-pinene | Antimicrobial, bronchodilator |
Antioxidant Properties
- Rosemary is one of the most potent antioxidant culinary/medicinal herbs, primarily due to carnosic acid and carnosol
- Rosemary extract is used as a food-grade antioxidant preservative (E392) in the European Union
- Antioxidant activity is well-documented in vitro and in food preservation but clinical relevance for disease prevention in humans is not established
Clinical Evidence Summary
Volume of Evidence
- Very limited. The evidence base for rosemary is primarily pharmacological, traditional, and preclinical. There are no large, well-designed RCTs for the approved digestive or rheumatic indications.
Key Studies
Digestive Indications
- No dedicated RCTs for rosemary monotherapy in functional dyspepsia were identified in the major clinical databases
- Pharmacological plausibility is well-established: the spasmolytic and choleretic activities of rosemary constituents are documented in multiple in vitro and animal studies
- Rosemary is used as a component of some multi-herb digestive preparations, but its individual contribution is difficult to isolate
Topical/Rheumatic Indications
- No dedicated RCTs for rosemary bath or topical preparations in rheumatic conditions were identified
- The rubefacient properties of camphor and 1,8-cineole are well-characterized pharmacologically
Cognitive/Aromatherapy (Exploratory — Not an Approved Indication)
| Study | Design | N | Key Finding |
|---|---|---|---|
| Moss & Oliver 2012 | Controlled, aroma exposure | 20 | Exposure to rosemary aroma improved speed and accuracy on cognitive tasks; plasma 1,8-cineole levels correlated with performance |
| Pengelly et al. 2012 | RCT, DB, PC | 28 | 750 mg dried rosemary leaf improved memory speed in older adults; highest dose (6000 mg) impaired memory |
- These cognitive studies are of scientific interest but do not form the basis of any approved clinical indication
Evidence Gaps
- No RCTs for the Commission E or EMA approved indications (dyspepsia, rheumatic topical use)
- No dose-response data from human trials
- No head-to-head comparisons with other carminatives or antispasmodics
- Long-term safety data from clinical trials is absent
European vs US/Anglophone Consensus
| Aspect | European Consensus | US/Anglophone Consensus |
|---|---|---|
| Regulatory status | Commission E approved; EMA traditional use monograph; registered herbal medicine in Germany and other EU countries | Dietary supplement; GRAS status as food flavoring (FDA); no therapeutic claims evaluated |
| Medicinal use | Recognized phytomedicine for dyspepsia and topical rheumatic support; available in pharmacies as teas, tinctures, bath additives | Primarily viewed as a culinary herb and flavoring; medicinal use is niche |
| Topical/bath use | Traditional use of rosemary baths for rheumatic complaints and circulatory stimulation is well-established in German-speaking countries (Rosmarinbad) | Bath therapy tradition is not widespread; topical use mainly limited to aromatherapy |
| Antioxidant recognition | Approved as food antioxidant (E392); recognized for preservative and potential health properties | Recognized primarily in food science contexts; less emphasis on medicinal antioxidant role |
| Aromatherapy | Used in clinical aromatherapy in some European hospitals and clinics | Growing aromatherapy market but outside mainstream medicine |
| Clinical evidence perception | Accepted on the basis of traditional use and pharmacological plausibility despite limited RCTs | Viewed with more skepticism due to absence of clinical trial evidence |
Safety Profile
Contraindications
- Known hypersensitivity to rosemary or other Lamiaceae plants
- Rosemary essential oil should not be applied to the face of infants or small children (risk of laryngospasm/glottis spasm from camphor/1,8-cineole)
- Severe hepatic impairment (precautionary)
Drug Interactions
- No clinically significant drug interactions have been documented at standard therapeutic doses
- In vitro data suggests potential for minor CYP enzyme modulation (CYP1A2, CYP3A4), but no clinical reports of relevant interactions exist
- Theoretical additive effect with anticoagulants has been mentioned in some sources but is not supported by clinical evidence
Side Effects
- Generally very well tolerated at recommended doses
- Contact dermatitis (rare; primarily with essential oil or fresh plant contact in sensitized individuals)
- Gastric irritation at high doses (uncommon)
- Essential oil toxicity (overdose): seizures, vomiting, pulmonary edema; this applies to undiluted essential oil ingestion and is not relevant at recommended doses of leaf preparations
Pregnancy/Lactation
- Avoid in pregnancy in medicinal doses: Rosemary has traditional emmenagogue properties; high doses may stimulate uterine contractions. Culinary amounts are considered safe
- Lactation: Insufficient data; medicinal use not recommended during breastfeeding. Culinary use is safe
- Not recommended for children under 12 years in medicinal doses (EMA recommendation)
Clinical Dosage
Standard Dosage Forms
| Form | Preparation | Daily Dose | Notes |
|---|---|---|---|
| Dried leaf (infusion) | 2 g per cup, hot water infusion | 4-6 g daily (2-3 cups) | Commission E dose; steep covered for 15 minutes |
| Tincture (1:5, 70% ethanol) | Liquid extract | 2-4 mL, three times daily | Traditional form |
| Essential oil (external) | 6-10% in carrier oil or ointment | Apply to affected area 2-3 times daily | For rheumatic/muscular complaints |
| Bath additive | 50 g dried leaf per bath, or 5-10 mL essential oil | 1 bath daily | Traditional rosemary bath (Rosmarinbad) for rheumatic conditions; water temperature 35-38 degrees C |
| Liquid extract (1:1, 45% ethanol) | Standardized liquid extract | 1-2 mL, three times daily | Less commonly used than infusion |
Commission E Recommended Doses
- Internal: 4-6 g cut leaf daily as infusion
- External: 50 g leaf per full bath; or 10 mL essential oil per full bath
EMA/HMPC Recommended Doses
- Herbal tea (internal): 2 g in 150 mL boiling water, 2-3 times daily
- Tincture: 10 mL per dose, up to 3 times daily (1:5, 70% ethanol)
- Bath (external): 50 g per 1 liter water, added to a full bath
- Duration: Consult a physician if symptoms persist beyond 2 weeks
Sources
- EMA/HMPC Herbal Monograph on Rosmarinus officinalis L., folium and aetheroleum (EMA/HMPC/13631/2009)
- EMA/HMPC Assessment Report on Rosmarinus officinalis L., folium and aetheroleum
- Commission E Monograph: Rosmarini folium (1990)
- European Pharmacopoeia Monograph: Rosemary leaf (Rosmarini folium)
- Begum A, et al. An in-depth review on the medicinal flora Rosmarinus officinalis (Lamiaceae). Acta Sci Pol Technol Aliment. 2013;12(1):61-73
- Moss M, Oliver L. Plasma 1,8-cineole correlates with cognitive performance following exposure to rosemary essential oil aroma. Ther Adv Psychopharmacol. 2012;2(3):103-113
- Pengelly A, et al. Short-term study on the effects of rosemary on cognitive function in an elderly population. J Med Food. 2012;15(1):10-17
- Raskovic A, et al. Antioxidant activity of rosemary (Rosmarinus officinalis L.) essential oil and its hepatoprotective potential. BMC Complement Altern Med. 2014;14:225
- European Food Safety Authority. Scientific opinion on the use of rosemary extracts as a food additive. EFSA J. 2008;721:1-29
Connections
- Compare with Peppermint as a fellow carminative and spasmolytic herb for dyspepsia; peppermint has stronger clinical evidence (particularly for IBS)
- Related to Lemon Balm as a Lamiaceae family member with shared rosmarinic acid content and overlapping digestive indications
- Related to Thyme as a Lamiaceae herb with shared essential oil components (1,8-cineole, borneol) and similar safety profile
- Compare with Lavender for topical analgesic and aromatherapy applications; both are Lamiaceae herbs used externally for pain and stress
- The antioxidant compounds (carnosic acid, rosmarinic acid) in rosemary are shared with Sage, reflecting their close botanical relationship
Related Herbs
Lavender
Lavandula angustifolia
A Very Strong
High Silexan (Lasea) is a proprietary standardized oral lavender oil preparation (80 mg/day) that has emerged as one of the best-evidenced herbal anxiolytics. Five major RCTs (n=1,213 for the placebo comparisons) demonstrate efficacy comparable to lorazepam 0.5 mg/day and paroxetine 20 mg/day for generalized anxiety disorder, with a superior safety profile (non-sedating, no abuse potential, no dependence). Its mechanism is novel: inhibition of voltage-gated calcium channels (primarily T-type and N-type), similar in concept to pregabalin but with a different binding site and without sedation. Recent data (2024) also suggest efficacy in mild-to-moderate depression. The EMA/HMPC has registered Silexan as a traditional herbal medicine for temporary anxiety in patients aged 12+.
Read more →
Lemon Balm
Melissa officinalis
B Strong
Moderate Lemon balm is a versatile medicinal herb in the European tradition with three distinct therapeutic profiles: (1) internal use for mild anxiety and sleep disturbance (traditional use, moderate evidence), (2) cognitive enhancement via acetylcholinesterase inhibition (emerging evidence, relevant to Alzheimer's), and (3) topical antiviral activity against herpes simplex (good clinical evidence from RCTs). Its mechanism involves modulation of GABAergic, cholinergic, and serotonergic systems, with rosmarinic acid as the principal bioactive constituent. The EMA/HMPC approved it in 2013 as a traditional medicine for mild mental stress, sleep support, and mild GI complaints. It has an excellent safety profile.
Read more →
Peppermint
*Mentha x piperita*
C Moderate
Moderate See full monograph below.
Read more →